Adeno Associated Virus Vector Manufacturing Market To Reach $2.78 Billion By 2030

Adeno Associated Virus Vector Manufacturing Market Growth & Trends

The global adeno associated virus vector manufacturing market size is expected to reach USD 2.78 billion by 2030, registering a CAGR of 18.55% from 2025 to 2030, according to a new report by Grand View Research, Inc. This growth is attributed to the increasing prevalence of chronic diseases like cancers, cystic fibrosis, Duchenne muscular dystrophy, retinitis pigmentosa, and many more. Adeno-associated virus (AAV) vector plays a vital role in the treatment of these diseases. AAV vectors also have a wide range of applications in gene therapy delivery. Companies are engaged in collaborations, mergers, and partnerships for innovative product launches with advancements in R&D.

For instance, in December 2021, Astellas and Dyno Therapeutics entered into a strategic collaboration to develop an NGS-based AAV vector for gene therapy by using Dyno’s CapsidMap platform for cardiac and skeletal muscle. Such initiatives are expected to expand their market presence in the development and production of antibodies, which is likely to support the growth of the market. The COVID-19 pandemic had a positive impact on the industry. As adeno associated virus has vast applications in vaccine manufacturing, various companies were involved in the race to manufacture the vaccine to treat COVID-19. This resulted in a sudden spur in the demand for manufacturing these vectors.

For instance, in September 2021, CEVEC and UCB entered into a strategic agreement for the use of ELEVECTA AAV vector manufacturing technology for R&D and gene therapy applications. As gene therapy involves alterations or modifications in the set of genes, it has raised many ethical issues. As a result, the U.S. government restricted the usage of federal funds for research on germline gene therapy in people. Gene therapy can help save future generations of a family from acquiring a particular genetic disorder. However, it is anticipated to affect the fetus’s development significantly. The high demand for vaccines, gene therapeutics, CGMP drugs, and products to treat & cure acute diseases and the demand for improving patient care also propel the industry growth. Thus, global stakeholders are investing significantly in expanding their production capacities to fulfill the growing demands.

 Request a free sample copy or view report summary: Adeno Associated Virus Vector Manufacturing Market

Adeno Associated Virus Vector Manufacturing Market Report Highlights

• By the scale of operations, the commercial segment dominated the industry in 2024. Owing to the increasing R&D investment by companies and demand from vaccine manufacturers

• The neurological diseases therapeutic area segment captured the largest share in 2024 due to the high prevalence of chronic neurodegenerative diseases and the effectiveness of the adeno associated virus vector-based therapies to treat these diseases

• Vaccine is considered a key application segment, which held the largest revenue share in 2024 and is likely to remain dominant throughout the forecast period due to the rising demand for vaccine therapeutics and increasing investments & funds for the production of vaccines

• North America has established a strong regional position. The increasing incidence of cancer and high R&D expenditure is encouraging companies in the region to undertake product development, which drives the regional market

Adeno Associated Virus Vector Manufacturing Market Segmentation

Grand View Research has segmented global adeno associated virus vector manufacturing market on the basis of scale of operations, method, therapeutic area, application, and region:

Adeno Associated Virus Vector Manufacturing Scale of Operations Scope Outlook (Revenue, USD Million, 2018 - 2030)

• Clinical

• Preclinical

• Commercial

Adeno Associated Virus Vector Manufacturing Method Scope Outlook (Revenue, USD Million, 2018 - 2030)

• In Vitro

• In Vivo

Adeno Associated Virus Vector Manufacturing Therapeutic Area Scope Outlook (Revenue, USD Million, 2018 - 2030)

• Hematological Diseases

• Infectious Diseases

• Genetic Disorders

• Neurological Disorders

• Ophthalmic Disorders

• Others

Adeno Associated Virus Vector Manufacturing Application Scope Outlook (Revenue, USD Million, 2018 - 2030)

• Cell Therapy

• Gene Therapy

• Vaccine

Adeno Associated Virus Vector Manufacturing Regional Scope Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • South Korea

  • Australia

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players of Adeno Associated Virus Vector Manufacturing Market

• F. Hoffmann-La Roche Ltd

• Charles River Laboratories

• Oxford Biomedica PLC

• WuXi AppTec

• Yposkesi, Inc.

• Sarepta Therapeutics, Inc.

• Pfizer Inc.

• Genezen

• Creative Biogene

• GenScript (ProBio)